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Molecular mechanisms and targets of cyclic guanosine monophosphate (cGMP)
accounting for vascular smooth muscles (VSM) contractility are reviewed. Mathe-
matical models of five published mechanisms are presented, and four novel mech-
anisms are proposed. cGMP, which is primarily produced by the nitric oxide (NO)
dependent soluble guanylate cyclase (sGC), activates cGMP-dependent protein
kinase (PKG). The NO/cGMP/PKG signaling pathway targets are the mechanisms
that regulate cytosolic calcium ([Ca2+]i) signaling and those implicated in the Ca
2+-
desensitization of the contractile apparatus. In addition to previous mathematical
models of cGMP-mediated molecular mechanisms targeting [Ca2+]i regulation, such
as large-conductance Ca2+-activated K+ channels (BKCa), Ca2+-dependent Cl
channels (ClCa), Na+/Ca2+ exchanger (NCX), Na+/K+/Cl cotransport (NKCC),
and Na+/K+-ATPase (NKA), other four novel mechanisms are proposed here based
on the existing but perhaps overlooked experimental results. These are the effects of
cGMP on the sarco/endo- plasmic reticulum Ca2+-ATPase (SERCA), the plasma
membrane Ca2+-ATPase (PMCA), the inositol 1,4,5-trisphosphate (IP3) receptor
channels type 1 (IP3R1), and on the myosin light chain phosphatase (MLCP), which
is implicated in the Ca2+-desensitization. Different modeling approaches are
presented and discussed, and novel model descriptions are proposed.
Keywords: vascular smooth muscle, contraction, relaxation, nitric oxide, cyclic
guanosine monophosphate, protein kinase G, Ca2+ signaling, desensitization,
mathematical model, ionic fluxes
1. Introduction
Cyclic guanosine 30,50-monophosphate (cGMP) is an intracellular second-
messenger that mediates a broad spectrum of physiologic processes in multiple cell
types within the cardiovascular, gastrointestinal, urinary, reproductive, nervous,
endocrine, and immune systems. In particular, cGMP signaling plays a vital role in
the endothelium, vascular smooth muscle cells (VSMC), and cardiac myocytes.
cGMP was first synthesized in 1960, and soon after, its endogenous production was
detected in rats. In the late 70s, two separate experiments confirmed that the gas
nitric oxide (NO) stimulated cGMP production by activating soluble guanylate
1
cyclase (sGC). In 1980, it was reported that a diffusible substance causing vasodi-
latation is released from the endothelium. The so-called endothelium-derived
relaxing factor (EDRF) was identified seven years later as NO. See [1] for review.
The molecular mechanisms of cardiovascular NO signaling are not entirely
understood. Still, it is currently accepted that many effects are mediated, at least in
part, via cGMP-dependent pathways. Within the cardiovascular system, these
signaling pathways play a vital role in vasodilatation as well as in proliferation,
migration, differentiation, and inflammation of VSMC and endothelial cells (ECs),
in the modulation of myocyte contractility as well as of cardiac remodeling and
thrombosis [2–4]. Impaired functioning at any signaling step from the synthesis
through the effector activation and the degradation process of either NO or cGMP
accounts for numerous cardiovascular diseases, such as hypertension, athero-
sclerosis, cardiac hypertrophy, and heart failure [3, 4]. Hence, these signaling
pathways represent the potential targets for pharmacological treatment.
2. Nitric oxide (NO) and cyclic guanosine monophosphate (cGMP)
production and degradation
Various stimuli can trigger relaxation responses of VSMC via the production and
signaling of NO in the vascular endothelium. These are endogenous neurotransmit-
ters (e.g., substance P and acetylcholine), humoral substances (e.g., bradykinin),
and mechanical stimuli (e.g., the increase in hemodynamic shear stress or
intraluminal pressure). They all trigger a complex cascade of biochemical reactions,
accounting for either the mobilization, activation, or increase in the catalytic activ-
ity of NOS to produce NO or for upregulation of its gene expression. In the cardio-
vascular system, most of NO is produced in the endothelium by the endothelial
NOS (eNOS). eNOS is also detected in cardiac myocytes, platelets, certain neurons,
and kidney tubular epithelial cells. The other two isoforms are neuronal- and
inducible- NOS (nNOS and iNOS, respectively). The former is mainly located in the
nervous system, and the latter, which is induced by cytokines, is predominantly
found in the immune system. They all catalyze the oxidation of the amino acid L-
arginine into L-citrulline, where the by-product is NO [5].
Sensing of shear stress is still under intensive research since it is mediated by
rapid and almost simultaneous activation of various membrane molecules and
microdomains, including ion channels, tyrosine kinase receptors, G-protein-
coupled receptors, caveolae, adhesion proteins, cytoskeleton, glycocalyx, primary
cilia, and filaments [6]. Though the underlying biochemical signaling processes are
not entirely understood, three main mechanisms of mechanotransduction were
proposed. The first one involves the mechanisms which account for the entry of
Ca2+ across the EC plasma membrane either via capacitive Ca2+ entry (CCE) [7] or
via activation of mechanosensing ion channels (MSICs) [8]. Both processes lead to
further increases in [Ca2+]i, its consequent interaction with calmodulin (CaM), and
finally to NOS activation. The other two mechanisms cross-correlate many signaling
pathways mediated by G protein-coupled receptors (GPCR) and integrins involving
protein kinases A, B, C, and G (PKA, Akt, PKC, and PKG, respectively), as well as
phosphatidylinositide 3-kinase (PI3K). These signaling pathways regulate the acti-
vation of different nuclear factors affecting NOS gene expression [9], the recruit-
ment of NOS from caveolae, the phosphorylation of NOS, and the cytosolic [Ca2+]i
concentration and signaling [6].
Downstream the NO production cGMP is produced either by the soluble or the
membrane-bound particulate guanylate cyclases, sGC and pGC, respectively, in
response to either elevated NO or brain and atrial natriuretic peptides (BNP and
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ANP, respectively). Natriuretic peptides (NPs) activate pGC, while NO diffuses
into the cytosol, binds to, and activates sGC. cGMP exerts its action predominantly
through binding and activating its target, cGMP-dependent protein kinase (PKG)
[3]. There are two other types of cGMP-target effector molecules. The first type is
phosphodiesterases (PDEs), which also degrade other cyclic nucleotides. The sec-
ond type is nonselective cation channels, which are present in the visual and olfac-
tory systems. PDEs degrade cGMP and, hence shape its spatiotemporal levels.
CGMP also cross-regulates cyclic adenosine monophosphate levels (cAMP) since
other PDEs (e.g. PDE2) that degrade both cAMP and cGMP are stimulated by
cGMP [10]. In addition to PDE5, which selectively degrades cGMP, several other
PDE isoforms can hydrolyze both, cGMP and cAMP. These are PDE1, PDE2, and
PDE3. The strategy of inhibiting PDEs to enhance cGMP and related signaling has
already been successfully used with the PDE5 inhibitors, especially sildenafil, to
treat erectile dysfunction, pulmonary hypertension, and chronic heart failure [10].
Other cGMP-elevating drugs, such as nitrovasodilators that donate NO, and various
NP analogs, have also been successfully used in humans to treat cardiovascular
diseases. NO-generating drugs such as glyceryl trinitrate or sodium nitroprusside
have been used to treat angina pectoris in humans for more than 100 years [11].
3. Calcium-contraction coupling in vascular smooth muscle cells
(VSMC)
The contractile state of VSMCs is regulated dynamically by hormones and neu-
rotransmitters via the increase of the cytosolic calcium concentration ([Ca2+]i). Ca
2+
is mostly released from its intracellular store sarcoplasmic reticulum (SR) via IP3
sensitive or ryanodine receptor channels (IP3R and RyR, respectively). In part, Ca
2+
entry to the cytosol could be ascribed to the fluxes across the plasma membrane via
the Ca2+- selective voltage-dependent channels. The rise in [Ca2+]i initiates binding
of Ca2+ to CaM and the consequent interactions of myosin light chain kinase
(MLCK) with Ca2+/CaM complexes. Active MLCK is the one that is bound with the
Ca4CaM complex. Active MLCK phosphorylates the regulatory myosin light chain
(MLC), enabling the attachment of myosin heads to the actin filaments and cross-
bridge cycling [12]. The smooth muscle cell’s contractile state is determined by the
extent of MLC phosphorylation regulated by the balance of MLCK and MLC phos-
phatase (MLCP) activities. The latter dephosphorylates MLC. High vascular tone is
maintained as long as the phosphorylation rate is higher than that of dephosphory-
lation. Relaxation occurs when [Ca2+]i decreases, which results in the dissociation of
Ca2+ from CaM and inactivation of MLCK. In that case, the activity of MLCP
predominates the activity of MLCK, and the active actin-myosin cross-bridge
cycling is not established. However, a passive latch state is possible [13]. The level of
smooth muscle contractility can also be modulated at constant [Ca2+]i. The protein
kinase C (PKC) and Rho kinase (ROCK) pathways play an essential role in regulat-
ing MLCP activity. They may cause diminished activity of MLCP and result in
increased levels of phosphorylated MLC and a higher tension at a given [Ca2+]i. This
increased contractility is called Ca2+ sensitization [12]. In reality, the process is
much more complex since it is composed of many cross-interacting pathways with
different feedbacks, nonlinear behavior of the interactions, dynamical changes of
many variables – especially [Ca2+]i [14]. In this complex system of interactions
[Ca2+]i signaling still represents a bottleneck according to its bow-tie structure of
encoding and decoding [15]. cGMP/PKG signaling occurs on both – the encoding
and the decoding sides and represents a predominant mechanism in regulating
vasoactivity, particularly vasorelaxation. More than ten substrates being
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phosphorylated in vivo by PKG were identified, and many of them take part in the
[Ca2+]i encoding and decoding processes [3, 16].
3.1 cGMP-dependent protein kinase (PKG)
The enzyme PKG belongs to the family of serine/threonine (Ser/Thr) kinases. In
mammals, PKG-I and PKG-II are encoded by different genes, prkg1 and prkg2,
respectively. PKG-I exists in two isoforms PKG-Iα and PKG-Iβ. PKG-I is present at
high concentrations in all smooth muscles, including the uterus, vessels, intestine,
and trachea. PKG-II is expressed in several brain nuclei, intestinal mucosa, kidney,
adrenal cortex, chondrocytes, and lung. Only PKG-Iα and PKG-Iβ are expressed in
the vascular system. See [3] for a review. All types of PKG are homodimers. Each
monomer contains a regulatory and a catalytic domain. Each of the PKG regulatory
domains binds two cGMP molecules allosterically with high cooperativity. The
affinities of the two binding sites on each of the subunits of PKG-Iα differ by
approximately tenfold. Binding sites occupied by cGMP induce significant confor-
mation changes in the molecular structure. By that, autoinhibition of the catalytic
center is released, and the basal activity is increased. Hence, the phosphorylation of
serine/ threonine residues of the target proteins as well as of the
autophosphorylation site is possible. All four binding sites have to be occupied with
cGMP for the fully active holoenzyme PKG [17]. PKG-I mediates both receptor-
triggered and depolarization-induced vasorelaxation by several mechanisms. Many
of them are not entirely understood, and some of them are still unknown. In
general, PKG-mediated relaxation is induced either by attenuation of [Ca2+]i and/or
desensitization of the contractile apparatus. The first effect is achieved by nega-
tively affecting the “[Ca2+] i-on” mechanisms and by positively affecting the
“[Ca2+]i-off” mechanisms. On the [Ca
2+]i-decoding part, PKG’s effect is concen-
trated mainly on the activation of the MLCP, which desensitizes the contractile
apparatus to [Ca2+]i [18].
3.2 “[Ca2+]i-on”mechanisms as targets of cGMP/PKG signaling
One of the primary targets of cGMP/PKG signaling to elevate [Ca2+]i is the IP3
receptor channel type 1 (IP3R1) and its correlated cGMP-associated kinase substrate
protein (IRAG). If IRAG is colocalized with IP3R1 and PKG-Iβ in the presence of
cGMP, it inhibits Ca2+ release through IP3R1 via its phosphorylation [19]. It was
shown that PKG-Iβ exclusively phosphorylated only the type 1 but not the type 2
and 3 IP3R in vivo and that both, PKG and PKA, phosphorylated IP3R1 in vitro in
gastric smooth muscles, which resulted in diminished IP3 and Ca
2+-induced Ca2+
release (ICICR) from the SR [20]. In vivo experiments on mice with mutated IRAG,
which did not interact with IP3R, showed that PKG/IRAG/ IP3R interactions indeed
decrease the receptor-triggered [Ca2+]i and hence contraction [21]. In the in vitro
experiments, it was also shown that PKG-Iβ phosphorylated IRAG but not IP3R
[22]. The same was confirmed with COS-7 transfected cells where the phosphory-
lation of IRAG resulted in the reduced Ca2+ release during concurrent activation of
PKA and PKG. The effect was observed for all three IP3R sub-types [23]. It is
supposed that IRAG signaling does not modulate basal tone but might be important
for blood pressure regulation under pathophysiological conditions [24].
PKG-Iα may also attenuate receptor-activated contraction via inhibition of IP3
production mediated by GPCR signaling [25] and interfering with phospholipase
C-β (PLC-β) [26]. It has been shown that the isoform PKG-Iα binds, phosphory-
lates, and activates the regulator of G protein signaling 2 (RGS2), which terminates
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the signal transduction of the contractile agonists mediated by the Gq-coupled
receptors and terminates thereby the activity of PLC [25]. It was also proposed that
PKG-Iα/RGS2 pathway might inhibit hormone receptor-triggered Ca2+ release and
vasoconstriction in vivo [27]. It has also been shown that PKG can directly phos-
phorylate PLC-β in vitro in cultured COS-7 cells and in vivo in aortic VSMC, which
blocked the activation of the enzymes correlated with the G-protein subunits and
attenuated agonist-induced IP3 production and Ca
2+ release [26].
There is also evidence that PKG may cause vasodilatation by suppressing the Ca2+
influx across the plasma membrane through the voltage-operated Ca2+ channels
(VOCC). cGMP/PKG has the opposite effect as cAMP/PKA on this type of channel.
The former inhibited and the latter enhanced L-type Ca2+ channel (LTCC) activity in
rabbit portal vein myocytes [28]. On the other hand, in rat cerebral arterial VSMC,
which express T-type Ca2+ channels (TTCC) PKA [29] and PKG [30] both had a
suppressing effect on their conductance. In both cases, a rightward shift of the
voltage-response curve was observed. A similar effect was observed for the
nonselective transient receptor potential cationic 1/3 channels (TRPC1/3) [31]. On
the other hand, the experiments on the macroscopic and single-channel Ca2+ currents
from guinea-pig basilar artery showed that the addition of 10 μM cGMP did not affect
single-channel properties, such as conductance, voltage dependence, the number of
open states, and different time constants, but significantly reduced the channel
availability [32].
3.3 “[Ca2+]i-off”mechanisms as targets of cGMP/PKG signaling
cGMP/PKG is supposed to enhance the activities of all three major Ca2+-removal
systems in VSMCs. The Primary [Ca2+]i-off mechanism is refilling the Ca
2+ stores
via sarco/endo- plasmic reticulum Ca2+-ATPase (SERCA). The increase in SERCA
activity in response to cGMP was first identified in isolated SR vesicles from cardiac
and smooth muscles [33]. Later it was demonstrated that NO-induced relaxation of
cultured VSMC from the aorta was associated with increased PKG-dependent
phospholamban (PLB) phosphorylation [34]. Using a solid-state nuclear magnetic
resonance (NMR) spectroscopy, it was found that PLB binds to SERCA allosterically
[35]. Moreover, the phosphorylation at Ser16 of PLB, which gradually lowers PLB
interaction with SERCA, was found to increase SERCA activity [35]. In gastric SMC,
cGMP-mediated Ca2+ uptake via SERCA was observed in vitro in a concentration-
dependent manner [36].
Experiments on cultured aortic VSMC provided evidence that cGMP also accel-
erates [Ca2+]i extrusion by stimulating the Na
+/ Ca2+ exchangers (NCX) at different
Na+ concentrations [37]. cGMP increased both forward and reversed Na+/ Ca2+
exchange modes by approximately 50% after adding 500 μM of membrane-
permeable cGMP analog. The [Ca2+]i pumping activity gradually increased with
cGMP concentration. Phosphorylation by PKG was proposed as the underlying
mechanism for this effect [37].
Another cGMP/PKG-mediated [Ca2+]i-off mechanism is the plasma membrane
Ca2+ ATP-ase (PMCA). The evidence was first obtained with experiments on iso-
lated proteins [38] and experiments performed on cultured VSMC [39]. All results
suggested that the phosphorylation of the PMCA by PKG was responsible for
stimulating the Ca2+-pumping activity, which was 2.4-fold higher after adding
500 μM of membrane-permeable cGMP analog. The leftward shift in the pumping
activity vs. [Ca2+]i dependence was also observed [39]. Experiment on isolated and
purified PMCA from porcine aorta [40] confirmed the previous two results at much
smaller cGMP concentrations.
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3.4 cGMP/PKG-dependent mechanisms that indirectly affect [Ca2+]i
The mechanisms by which cGMP/PKG signaling interferes with [Ca2+]i are
primarily linked with cell-membrane depolarization/hyperpolarization. Although
depolarization-induced contraction remains mostly unresolved, these mechanisms
are intensively studied [41]. One of the established targets of cGMP/PKG signaling
is the large-conductance Ca2+-activated K+ channel (BKCa). The modulation of
BKCa by different protein kinases in different smooth muscle tissues as well as the
sites and mechanisms of their action remain unresolved [42]. The activation BKCa
presumably hyperpolarises the cell membrane, thereby influences the gating of
voltage-operated Ca2+ channels and lowers [Ca2+]i. PKG-I is known to activate BKCa
either directly by phosphorylation [43] or indirectly via protein phosphatase regula-
tion [44]. Activation of BKCa in the presence of NO/cGMP in isolated rat afferent
arterioles attenuated extracellular Ca2+ influx upon KCl stimulation [45]. The role and
importance of BKCa in vasorelaxation were highlighted with the experiments
performed on BKCa-deficient mice. Their deletion led to a relatively mild increase in
blood pressure. However, it increased vascular tone in small arteries due to a com-
plete lack of spontaneous K+ efflux and, therefore, depolarised state of the mem-
brane, and reduced suppression of Ca2+ transients in response to cGMP [46].
Another mechanism by which cGMP/PKG signaling may affect [Ca2+]i influx is
via Ca2+-activated Cl channels [47]. These type of channels was observed in VSMC
of mesenteric resistance arteries. Since their activation required phosphorylation,
was sensitive to PKG inhibitors, and was evoked by adding PKG, it is believed that
the effect of cGMP on the Cl current is mediated through PKG [47]. The physio-
logical role of Ca2+-activated Cl channels is ambiguous since their excessive acti-
vation would promote an inward Cl current leading to cell depolarization,
activation of VOCC, increase in [Ca2+]i, and, hence, vasoconstriction.
Information on the effect of cGMP/PKG on Na+/K+ ATPase (NKA) [48] and
cotransport of Na+/K+/Cl (NKCC) [49] in terms of VSMC physiology is very
limited and vague. However, these mechanisms have been implicated in the math-
ematical models [50, 51]. It was reported that cGMP might increase the activity of
NKCC in vascular SMC of rat thoracic aorta by up to 3.5-fold [49]. In the canine
pulmonary artery SMC, nitroprusside/cGMP-mediated relaxation was accompanied
by increase NKA activity [48].
3.5 cGMP/PKG signaling targeting the Ca2+-desensitization mechanisms
PKG may also cause vasodilatation by desensitizing the contractile apparatus in
response to elevated [Ca2+]i, resulting from either MLCP activation or MLCK deac-
tivation. Both effects lead to MLC dephosphorylation, myosin cross-bridge detach-
ment, and relaxation even at high [Ca2+]i. The enzyme MLCP plays a major role in
the Ca2+-desensitization since it is not directly Ca2+-dependent, and it embodies
various possibilities for regulating its activity [52]. These different options arise
from its complex structure and widespread distribution in different tissues. MLCP
holoenzyme is composed of three subunits – catalytic (PP1c), regulatory (MYPT1),
and a small subunit (M20/M21). It is a Ser/Thr phosphatase that belongs to the
protein phosphatase type 1 (PP1) family. Active PP1c is required for its catalytic
activity, while MYPT1 targets the enzyme to its substrates and also autoregulates
the catalytic activity of PP1c. This autoregulation emerges because MYPT1 contains
different, for its structure and activity important, phosphorylation sites. In human
sequence, these phosphorylation sites are Thr696 and Thr853, which are phosphor-
ylated by ROCK [53] and other agonist-induced kinases. There are also Ser695 and
Ser852 phosphorylation sites on MYPT1, which are phosphorylated by PKA and
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PKG [54]. The residues Ser695 and Thr696 as well as Ser852 and Thr853, are close
within the MYPT1 sequence, and thus phosphorylation of one site prevents the
phosphorylation of the neighboring site. It was proposed and also demonstrated
that PKA or PKG-dependent phosphorylation of Ser695 and Ser852 prevents the
phosphorylation of Thr696 and Thr853 and vice versa [12, 54, 55].
The current hypothesis is that the phosphorylation of Thr696 and Thr853
induces such structural changes in MYPT1 that these phosphorylated sites interact
with the MLCP catalytic subunit PP1c [56] and is supported by the fact that MYPT1
is quite flexible at this part of the structure. Moreover, the sequences around
Thr696 or Thr853 are similar to that of Ser19, where MLC is phosphorylated [57]. It
is hypothesized that P-Thr696 and P-Thr853 may represent either substrate analogs
to P-Ser19 of MLC or a potent autoinhibitory site docking to the PP1c catalytic
subunit of MLCP [56]. In all these scenarios, the MLCP-dependent rate of MLC
dephosphorylation is decreased. On the other hand, if MYPT is phosphorylated at
Ser695 and Ser852 beforehand, Thr696 and Thr853 phosphorylation is blocked
[54, 56].
Phosphorylation of Thr853 is a less potent inhibitor of MLCP than Thr696 [56].
It was also reported that PKA could phosphorylate all four sites, Ser695, Thr696,
Ser852, Thr853, simultaneously. However, such a form of MYPT1 did not inhibit
PP1c [58]. Another possibility of MLCP activity inhibition is binding the phosphor-
ylated form of PKC-potentiated phosphatase inhibitor protein of 17 kDa (CPI-17) to
the catalytic subunit PP1c. The phosphorylation increases the affinity of CPI-17 for
PP1c by approximately 1000-fold, resulting in suppressed MLCP activity [59]. CPI-
17 is expressed predominantly in tonic smooth muscles with slow and sustained
contraction, especially in VSMC from the aorta and femoral arteries. The enzymes
linked with the phosphorylation of CPI-17 are PKC, ROCK, zipper-interacting pro-
tein kinase (ZIPK), integrin-linked kinase (ILK). However, PKC and ROCK are
most commonly mentioned [60]. ROCK signaling interferes with PKG and PKA
signaling since PKA and PKG phosphorylate RhoA, the ROCK activator. Increased
level of RhoA phosphorylation attenuates ROCK activity. In this way, PKGmediates
vasorelaxation via reduced activity of ROCK and the correlated reduced inhibition
of MLCP. That leads to faster MLC dephosphorylation and relaxation [61].
The role of PKC and ROCK in the stimulation-contraction coupling is still not
well understood [62]. It is also possible that their role and importance in different
smooth muscles is different. However, it is believed that CPI-17 phosphorylation
and the corresponding inhibition of MLCP is the predominant process of the early
phase of contraction. It was reported that PKC is believed to be primarily responsi-
ble for fast CPI-17 phosphorylation during the early phase of vasoconstriction, and
ROCK was found responsible for slow, sustained CPI-17 phosphorylation during the
sustained phase of contraction [63]. On the other hand, in the rat airways, ROCK
activation and the consequent MLCP inhibition contributed to the early phase of the
smooth muscles’ contractile response. Whatever the agonist in that system was, the
ROCK inhibitor Y27632 did not modify the basal tension. Still, it decreased the
amplitude of the short duration response without altering the superimposed
delayed contraction [64]. That indicates that in rat airway SMC, ROCK plays a
major role in CPI-17 phosphorylation and that other kinases are responsible for
Thr696 and Thr853 phosphorylation [62].
Moreover, PKG may affect MLCP activity also by the phosphorylation of
telokin, which is a smooth muscle-specific protein whose sequence is identical to
that of the noncatalytic terminus of MLCK. Telokin does not increase MLCP activity
per se but acts synergistically with PKA and PKG [65]. By binding to either phos-
phorylated MYPT1 and/or phosphorylated MLC, telokin is supposed to facilitate the
interaction between the enzyme and its substrate and de-inhibits the auto-
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suppressed MLCP activity emerging from Thr696 and Thr853 phosphorylation.
This mechanism results in an increased rate of MLC dephosphorylation [66]. The
majority of the described mechanisms and targets of cGMP/PKG signaling are
summarized in Figure 1. 11 targets are depicted, from which 9 of them are
described by mathematical models presented in the following chapter.
4. Mathematical modeling of cGMP/PKG-mediated ionic fluxes and
Ca2+-desensitization of the contractile apparatus
The first attempt to build a whole-cell-like model of VSMC, also considering the
NO/sGC/cGMP signaling cascade, was performed by Yang et al. [67]. They
upgraded their existing models for rat cerebrovascular arteries [68]. The model [67]
predicted the NO-induced cGMP production and the corresponding attenuation of
Figure 1.
Molecular mechanisms and targets of cyclic guanosine monophosphate (cGMP)/protein kinase G (PKG)
signaling in vascular smooth muscle cells (VSMCs) described in chapters 4.1 to 4.9 (full dark red lines denoted
with Ch. 4.1 to 4.9) and others described in the text (dashed dark red lines). For explanation see text.
Abbreviations used: GPCR (G protein-coupled receptor), RGS2 (regulator of Gq protein signaling 2), Gq (G
protein), PLC (phospholipase C), PKC (protein kinase C), IP3 (inositol 1,4,5-trisphosphate), NO (nitric
oxide), NPR (natriuretic peptide receptor), NP (natriuretic peptide), GTP (guanosine 50-triphosphate),
cGMP (cyclic guanosine monophosphate), 5’-GMP (guanosine 50-monophosphate), pGC (particulate
guanylate cyclase), sGC (soluble guanylate cyclase), PDE5 (phosphodiesterase 5), BKCa (large-conductance
Ca2+-activated K+ channels), ClCa (Ca2+-dependent Cl channels), VOCC (voltage-operated Ca2+ channel),
NCX (Na+/Ca2+ exchanger), NKA (Na+/K+-ATPase), NKCC (Na+/K+/Cl cotransport), PMCA (plasma
membrane Ca2+-ATPase), RhoA (ROCK activator), ROCK (rho kinase), CPI-17 (PKC-potentiated
phosphatase inhibitor protein of 17 kDa), PP1c (MLCP catalytic subunit), MYPT1 (MLCP regulatory
subunit), M20 (MLCP small subunit), MLCP (myosin light chain phosphatase),T696/ T853 (threonine 696/
853 of the MYPT1), S695/S852 (serine 696/853 of the MYPT1), MLCK (myosin light chain kinase), MLC-
20 (20 kDa myosin light chain), Ca4CaM (calmodulin with bound 4 Ca
2+), Ca2+-CaM (Ca2+-calmodulin
complexes), SR (sarcoplasmic reticulum), SERCA (sarco/endo- plasmic reticulum Ca2+-ATPase), PLB
(phospholamban), [Ca2+]i (cytosolic Ca
2+ concentration), IRAG (IP3R1-correlated cGMP-associated kinase
substrate protein), IP3R1 (1,4,5-trisphosphate receptor channel type 1), P (phosphorylated form of protein).
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[Ca2+]i, Ca
2+-desensitization of the contractile apparatus, and the reduction in force.
In terms of cGMP-mediated target-regulation, they considered the effects on the
BKCa and the contractile mechanism. Model simulations reproduced major
NO/cGMP-induced VSMC relaxation effects. Additionally, cGMP was also consid-
ered in sGC desensitization, limiting cGMP production well below maximum [67].
The activating effect of NO/cGMP on BKCa was assumed as cGMP-dependent and
partially NO-dependent.
In 2007 and 2008, another two whole-cell-like models for VSMC were presented
[50, 51]. However, both focused only on [Ca2+]i signaling and did not consider the
processes of the contractile apparatus. Jacobsen et al. [50] focused primarily on the
role of Ca2+-dependent Cl channels that may cause the transitions between differ-
ent types of [Ca2+]i signals in rat mesenteric small arteries upon α-adrenoreceptor
stimulation. Instead of cGMP’s influence on BKCa, they considered the cGMP-
dependent mechanisms of Ca2+-dependent Cl channels and NKA. Kapela et al. [51]
focused primarily on the plasma membrane electrophysiological properties and
considered eleven ionic currents across the plasma membrane. Four of them con-
sidered cGMP-dependent mechanisms, i.e. Ca2+-dependent Cl channels, BKCa,
NCX, and NKCC. The model’s purpose was to provide a working database of the rat
mesenteric SMC physiological data. It was considered as the building block of the
future multi-cellular models of the vascular wall [51].
4.1 The model of cGMP-mediated current through the large-conductance
Ca2+-activated K+ channels (BKCa)
BKCa is the most frequently modeled cGMP-dependent mechanism accounting
for [Ca2+]i signaling. The first model of Yang et al. [67] was based on the experi-
mental studies of Zhou et al. [69], who suggested that PKG stimulates the activity of
two isoforms of BKCa either by phosphorylation of the channel or its regulatory
proteins. The resultant effect on the potassium electric current (IK) was modeled
with a left-shift of the voltage dependency of equilibrium open probability (PK,o)
towards more negative potentials [67]. The complete mathematical description of
[68] follows the Hodgkin-Huxley formalism. The general expression forIK is:
IK ¼ gKPK,o Vm  VKð Þ, (1)
where gKis a channel conductance, PK,o is open probability or gating of the
channel and Vm  VKð Þ is the driving force of the current, where Vm is a membrane
potential, and the VK is the Nernst equilibrium potential. Eq. (1) is analogous to
Ohm’s law. The overall gating factor PK,o consists of two parts – a fast gating term
(PK,f ) and a slow gating term (PK,s):
PK,o ¼ fKPK,f þ sKPK,s, (2)
where fK is a fraction of fast channels, and sK is a fraction of slow channels. Fast
and slow gating terms are described with a first-order ordinary differential equation
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where τK,f and τK,s are the characteristic opening times and PK,ois an equilibrium
open probability, which is a sigmoidal function of the membrane potential (Vm):
PK,o ¼
1
1þ e VmVK,1=2ð Þ=SK,0
: (5)
The parameter’s value S0,K represents the slope of the sigmoidal function, and its
sign defines the orientation (declining/ increasing). Typically, V1=2,K is a parameter
and represents the membrane potential, at which half-maximal value PK,o is
achieved; however, here, it is a function of [Ca2+]i, [cGMP], and [NO]:





 VK,0  VK,cGMPRK,cGMP  VK,NORK,NO, (6)
where VK,0 is a basal value of V1/2, and VK,NO, VK,cGMP and VK,Ca are maximal














where ncGMP,K and nNO,K are the Hill coefficients and, KcGMP,K and KNO,K
are the half-saturation constants. The same notation for Hill function
parameters is used elsewhere in the text. The descriptions of all parameters are
given in tables.
Authors Kapela et al. [51] used almost the same approach as Yang et al. [67]. In
the former cas the authors used the Goldman-Hodgkin-Katz model to describe the











where Am is a cell-membrane surface area, NBKCa is a channel density, PBKCa is a
single channel permeability, Vm is a membrane potential, [K]o and [K]i are the
external and internal potassium concentrations, respectively, F is a Faraday
constant, R is the universal gas constant, and T is the absolute temperature. These
cell-specific and general parameter values could be found in [51]. cGMP-dependent
gating PK,o is defined the same as above in Eqs. (2)–(8).
The comparison of parameter values presented in Table 1 reveals similarities but
also differences. The model of Kapela et al. [51] was written more specifically for
the rat mesenteric arteriole, whereby the parameters for the BKCa were such that
they fitted experimental data of [70]. In contrast, the model of Yang et al. [67] was
compared with the experimental data for rabbit femoral arteries [71], and the
parameters for BKca accounted for [72].
4.2 The model of cGMP-mediated current through the Ca2+ activated
Cl channels (ClCa)
The model was first proposed by Jacobsen et al. [50] and was based on
the measurements performed on the rat mesenteric resistance arteries [47].
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The Cl electric current (ICl) across the plasma membrane is defined as that for
potassium in Eq. (1):
ICl ¼ gClPCl,o Vm  VClð Þ, (10)







but the equilibrium open probability PCl,o is not defined according to the








þ KCa,cGMP,Cl 1 ρRcGMP,Clð Þð Þ
nCa,Cl
, (12)
where nCa,Cl, KCa,cGMP,Cl and ρ are parameters, and RcGMP,Cl is cGMP-dependent:
RcGMP,Cl ¼
cGMP½ ncGMP,Cl
cGMP½ ncGMP,Cl þ KncGMP,ClcGMP,Cl
: (13)
For ICl, Kapela et al. [51] used a similar approach as Jacobsen et al. [50].
However, the former authors applied slight modifications. The general description
of the Cl current is the same as in [50] (Eq. (10)), only the expression PCl,o is
different. Kapela et al. [51] considered that a fraction of Ca2+-dependent Cl
channels is cGMP dependent, and a fraction is cGMP-independent. That is evident
from the two terms within the expression for PCl,o:
Parameter Description Value [67] Value [51]
gK Overall maximal conductance of the BKCa 0.5 nS /
fK Fraction of fast channels 0.65 0.17
sK Fraction of slow channels 0.35 0.83
τK,f The characteristic time of fast-channel activation 0.5 ms 0.84 ms
τK,s The characteristic time of slow-channel activation 11.5 ms 35.9 ms
SK,0 The slope of the Povs. Vm function 30.8 mV 18.25 mV
VK,Ca Maximal Ca
2+-induced V1/2 shift 53.7 mV 41.7 mV
VK,0 Basal V1/2value 283.7 mV 128.2 mV
VK,cGMP Maximal cGMP-induced V1/2 shift 66.9 mV 76 mV
VK,NO Maximal NO-induced V1/2 shift 100 mV 46.3 mV
ncGMP,K Hill coefficient 2 2
nNO,K Hill coefficient 1 1
KcGMP,K Half saturation constant in the regulatory cGMP-
dependent Hill function
0.55 μM 1.5 μM
KNO,K Half saturation constant in the regulatory NO-
dependent Hill function
0.2 μM 0.2 μM
Table 1.
Parameter values for the cGMP-dependent Ca2+-activated K+ (BKCa) current.
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þ KCa,cGMP,Cl 1 ρRcGMP,Clð Þð Þ
nCa,Cl
, (14)
where RI,Cl is a cGMP-independent component and RcGMP,Cl is defined the same
as in Eq. (13). Parameter values and their descriptions are presented in Table 2.
The comparison of parameter values presented in Table 2 shows remarkable
similarity. However, there are two significant differences in the modeling approach.
Jacobsen et al. [50], who first proposed the cGMP-dependent model for ICl, defined
PCl,o as a time-dependent function, whereas Kapela et al. [51] proposed an equilib-
riummodel and omitted differential Eq. (11). On the other hand, they added a cGMP-
independent term (compare Eq. (12) and Eq. (14)). In both cases, the same reference
with experimental data for rat mesenteric arteries was used to determine the param-
eter values [47], except for the half-saturation constant in the cGMP-independent
term (KCa,Cl) of [51], which was determined for the rat portal vein SMC [73].
It is suggested that the effect of cGMP on Ca2+-activated Cl current is not likely
to be essential for the tonic receptor-activated contractile response but rather for
the synchronization among VSMCs as between VSMCs and ECs [47, 50, 74].
4.3 The model of cGMP-mediated current through the Na+/Ca2+ exchanger
(NCX)
The framework for the mathematical description of the plasma membrane
Na+/Ca2+ exchange (NCX) (INCX) in Kapela et al. was taken from the model of Di
Francesco and Noble 1985 [75], which was developed for the atrial myocytes.
Kapela et al. [51] adjusted the maximal exchanger conductivity, which is much
lower in SMC than in atrial myocytes, and added the effect of cGMP according to
































  , (15)
Parameter Description Values [50] Values [51]
gCl Overall maximal conductance 3.8 nS 5.75 nS
τCl The characteristic time constant of channel activation 50 ms /
nCa,Cl Hill coefficient 3 2
KCa,cGMP,Cl Half saturation constant in cGMP-dependent factor 0.4 μM 0.4 μM
ρ The determinant of cGMP influence on the half-
saturation constant
0.9 0.9
ncGMP,Cl Hill coefficient 3.3 3.3
KcGMP,Cl Half saturation constant in the regulatory cGMP-
dependent Hill function
6.4 μM 6.4 μM
KCa,Cl Half saturation constant in cGMP-independent term / 0.365 μM
RI,Cl Weight of the cGMP-independent term / 0.0132
Table 2.
Parameter values for the cGMP-dependent Ca2+-activated Cl current.
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where INCX,s is a scaling factor for INCX, dNCX is the denominator constant, γ is
voltage-dependence parameter, and RNCX,cGMP is a cGMP-dependent regulatory
function:
RNCX,cGMP ¼ 1þ fNCX,cGMP
cGMP½ 
cGMP½  þ KcGMP,NCX
, (16)
where fNCX,cGMP is an additional fold-increase in NCX current due to cGMP
and KcGMP,NCX is a half-saturation constant. Parameter values are presented in
Table 3.
In experiments [37], [Ca2+]i pumping activity gradually increased with cGMP
concentration. However, a 50% increase in Na+/ Ca2+ exchange was observed after
adding a large, probably unphysiological concentration (500 μM) of membrane-
permeable cGMP analog. Hence, the effects of low cGMP concentrations on the
overall [Ca2+]i and contractile response are expected to be small. That is also evident
from a large half-saturation constant (KcGMP,NCX) in the cGMP-dependent function
RNCX,cGMP. However, the overall effect should be tested by integrating all mecha-
nisms in a whole-cell-like VSMC model.
4.4 The model of cGMP-mediated current through the Na+/K+-ATPase (NKA)
The NKA pumps Na+ out and K+ in and has stoichiometry 3 Na+:2 K+. Jacobsen
et al. [50] modeled the whole-cell electric current through NKA (INaK) as in [68]:
INaK ¼ INaK,max
Kþ½ i












whereby the maximal current (INaK,max ) is considered as linearly cGMP-
dependent:
INaK,max ¼ k1,NaK,cGMP cGMP½   k2,NaK,cGMP: (18)
All parameter descriptions and their values are presented in Table 4.
In terms of membrane potential, increased NKA activity hyperpolarizes the
membrane and enhances the Ca2+ influx through VOCC, which is similar to the
effect of cGMP on BKCa. The effect of cGMP/PKG on NKA has not been studied
often. The mathematical model is built on a single measurement on purified pig
renal NKA at one single concentration of cGMP, which in addition to PKG increased
the activity 1.6-fold. cGMP alone did not change the activity, and PKG alone
increased it 1.2-fold [76]. Due to the lack of credible measurements, the reliability of
this model is limited.
Parameter Description Values [51]
INCX,s Current scaling factor 0.0487–0.487 pA
dNCX Denominator constant 3  10
4
γ Voltage-dependence parameter 0.45
fNCX,cGMP Additional fold increase in electric current due to cGMP 0.55
KcGMP,NCX Half saturation constant in cGMP-dependent term 45 μM
Table 3.
Parameter values for the cGMP-dependent Na+/ Ca2+ exchange (NCX) current.
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4.5 The model of cGMP-mediated current through the Na+/K+/Cl
cotransporter (NKCC)
Instead of cGMP-dependent NKA, Kapela et al. [51] modeled the cGMP influ-
ence on the Na+/K+/Cl cotransport (NKCC) having the 1:1:2 stoichiometry. The
expression describing the electric current for a particular ion (IiNaKCl, where i is
either Na, K, or Cl) was taken from [77] and upgraded with a cGMP dependency.
According to [77], electric currents of individual ions are defined according to the







Here only the electric current for Cl (IClNaKCl) is written:










where ZCl is the valence of Cl
, INaKCl is a cotransport current coefficient, and
Naþ½ , Kþ½  and Cl½  are the corresponding concentrations outside and inside
(subscripts o and i, respectively) of the cell. RNaKCl,cGMP represents the cGMP-
dependent regulation factor that is defined as:
RNaKCl,cGMP ¼ 1þ fNaKCl,cGMP
cGMP½ 
cGMP½  þ KcGMP,NaKCl
, (21)
where fNaKCl,cGMP is a fold-increase in cotransport current due to cGMP. All
parameters and their values are presented in Table 5.
Very little is known about the effect of cGMP on the NKCC. The model is more
or less built on one single reference [49], which also offers limited information for
Parameter Description Values [51]
INaKCl Cotransport current coefficient 0.106 pA
fNaKCl,cGMP Additional fold-increase in electric current due to cGMP 3.5
KcGMP,NaKCl Half-saturation constant in cGMP-dependent factor 6.4 μM
Table 5.
Parameter values for the cGMP-dependent Na+/K+/Cl cotransport (NKCC) current.
Parameter Description Values [50]
KK,NaK Half-saturation constant 1 mM
KNa,NaK Half-saturation constant 11 mM
nNaK,Na Hill coefficient 1.5
ΔV1 Electric potential shift 150 mV
ΔV2 Electric potential shift 200 mV
k1,NaK,cGMP cGMP-concentration weighted electric current 30 pA/μM
k2,NaK,cGMP Electric current constant 30 pA
Table 4.
Parameter values for the cGMP-dependent current trough Na+/K+-ATPase (NKA).
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determining the reliable parameter values. The knowledge of the overall impact of
NKCC on VSMC contraction is lacking. Hence, their inclusion in the cGMP-
dependent mechanisms seems speculative.
4.6 The model of cGMP-mediated Ca2+ flux through the sarco/endo-plasmic
reticulum Ca2+-ATPase (SERCA)
Here we present a novel model of cGMP-dependent activation of the SERCA
pump based on the solid-state NMR spectroscopy measurements [35] and the mea-
surements performed on the isolated gastric SMC [36]. The former experiment [35]
revealed the physical interactions between the SERCA and the PLB in either a
phosphorylated or dephosphorylated state, and the latter experiment [36] offered
the results on the increase in Ca2+ uptake as a function of cGMP. The experiments
performed on isolated lipid bilayer-bound proteins revealed that the PLB-
dependent SERCA activity regulation is allosteric and that SERCA activity depends
on the transient conformational equilibrium states of PLB [35]. It was found that
phosphorylation at Ser16 of PLB shifts the conformation of PLB towards a more
extended and SERCA-bound state, which is non-inhibitory [35]. Phosphorylation of
PLB was induced by β-adrenergic stimulation, and it was supposed that the phos-
phorylation was cAMP/PKA dependent [35]. However, the cGMP/PKG-I depen-
dent phosphorylation of PLB at Ser16 in contact with SERCA was previously shown
in vitro [33]. Gustavsson et al. [35] proposed that PLB does not function as a simple
on/off switch of SERCA. Still, its different conformational equilibrium states exert a
gradual control on SERCA activity. PLB phosphorylation does not cause complete
dissociation of PLB from SERCA, but it influences the conformational equilibrium
of PLB’s regulatory domain and shifts its populations towards the non-inhibitory
state. That relieves the inhibition of SERCA [35]. According to [35], different PLB/
SERCA states exhibit functioning that follows Michaelis–Menten kinetics with the
same Hill coefficient (n) and same (Vmax) but different half-saturation constant
(Km), which is lower for higher relaxation-agonist level. Since the effect of cGMP
solely on the half-saturation constant could not explain the increase in Ca2+ uptake
as a function of high cGMP concentration that was observed in vitro in gastric SMC
[36], we upgraded the model also by adding a cGMP-dependent regulatory factor
















where RSERCA,cGMP is a cGMP-dependent pumping rate regulatory factor, which
is according to [36] an increasing Hill function superimposed on the basal pumping
rate VSERCA,min . The Hill function represents the best fit to the measured data of
cGMP dependent increase in Ca2+ uptake [36]:
RSERCA,cGMP ¼ 1þ f SERCA,cGMP
cGMP½ nSERCA,cGMP,V




RCa,cGMP is a cGMP-dependent half-saturation constant regulatory factor in the
Eq. (22), which is according to the measurements [35] a decaying Hill function:
RCa,cGMP ¼ 1 fCa,cGMP
cGMP½ nSERCA,cGMP,K
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All parameter values and their descriptions are presented in Table 6.
It has to be noted that the parameter values for Eq. (25) were determined by the
best fit to only three measured values from [35], and that KSERCA,Ca,max is consid-
ered the same as in the existing model for VSMC [50]. In the case of VSERCA,min , the
best fit was done to five measured points [36].
The significance of the cGMP effect on SERCA is still debated, and it is chal-
lenging to consider it independently of other [Ca2+]i-off mechanisms. It is suggested
[78] that cGMP-dependent SERCA activity can play a significant role in modulating
smooth muscle [Ca2+]i, but its role in the cGMP-mediated relaxation is minor.
Therefore, it would be worth testing the significance of that mechanism on the
whole-cell-like VSMC model.
4.7 The model of cGMP-mediated current through the plasma membrane
Ca2+-ATPase (PMCA)
Yoshida et al. [40] demonstrated that PKG phosphorylated and stimulated
PMCA in a concentration-dependent manner. The experiment was conducted on
isolated and purified PMCA from the porcine aorta. Much smaller - physiological
cGMP concentration, 1 μM, than in previous experiments (500 μM) [38, 39], was
added to 10 μg/mL (roughly 0.2 μM) PKG at different free Ca2+ concentrations.
That increased PMCA activity by approximately 3-fold over the whole range of Ca2+
concentrations and slightly shifted the pumping activity towards the left. cGMP
alone did not affect the pump activity [40]. In modeling these effects, we use a
similar approach as for SERCA, which obeys Michaelis–Menten kinetics. However,
previous studies [50, 79] also included weak membrane-potential-dependence,

















Parameter Description Value References
nSERCA,Ca Hill coefficient 2.5 [50]
VSERCA,min Minimal Ca
2+ pumping rate 1.88  103 μM/s [50]




KcGMP,SERCA,V Half-saturation constant in the cGMP-
dependent regulatory Hill function
1.44  102 μM Recalculated by
fitting from [36]
nSERCA,cGMP,V Hill coefficient 0.092 Recalculated by
fitting from [36]
KCa,SERCA,max Maximal value of SERCA half-saturation
constant
0.07 μM [50]




KcGMP,SERCA,K Half saturation constant in the cGMP-
dependent regulatory Hill function
0.1 μM Recalculated by
fitting from [35]
nSERCA,cGMP,K Hill coefficient 1.2 Recalculated by
fitting from [35]
Table 6.
Parameter values for the cGMP-dependent Ca2+ efflux via SERCA.
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where IPMCA,min is a minimal pumping rate translated into electric current,
which is, according to [40], a function of PKG. Yoshida et al. [40] conducted all
their experiments at variable PKG concentrations and 5 to 20 times higher cGMP
concentration. Since all our functions were written as cGMP-dependent, we trans-
late PKG concentrations into cGMP by considering the active PKG:cGMP molar
ratio 1:4. The Hill function fitted to measured data [40] is superimposed on the
basal pumping current IPMCA,min and is here represented as a cGMP-dependent
regulatory factor:
RPMCA,cGMP ¼ 1þ f PMCA,cGMP
cGMP½ nPMCA,cGMP




Parameter values and their descriptions are presented in Table 7.
In Eq. (25), KCa,PMCA is a half-saturation constant. The value was determined by
fitting the Hill function to two sets of measured data [40], the control case, and the
PKG-dependent case, with 0.2 μMPKG and 1 μMcGMP. For the former case, the value
is 0.22 μM, and for the latter case, it is 0.14 μM. Since the change is rather small and
there are only two measured values available, we do not assume cGMP dependency in
this case. That decision is also supported by the results of [39] where the left-shift in
that value was only by 27% at supramaximal membrane-permeable cGMP analog
concentration (500 μM).We propose here the average value. Elsewhere the value is
similar (0.2 μM) [50, 79] and 0.17 μM [51]. nPMCA,Ca is also determined by fitting to the
same set of measured data [40]. The values were 0.7 and 0.5 for the control and the
PKG-dependent case, respectively. We propose here an average. Value 1 was used
elsewhere [50, 51, 79]. Fold-increase in electric current due to cGMP is quite large and
might impact the [Ca2+]i, which the whole-cell-like model could demonstrate.
4.8 The model of cGMP-mediated Ca2+ flux through the inositol
1,4,5-trisphosphate (IP3) receptor channels type 1 (IP3R1)
4.8.1 Variant A
The proposed model for cGMP-mediated IP3R1 deactivation is also presented
here for the first time. The framework of the proposed mechanism is the model of
Parameter Description Value References
nPMCA,Ca Hill coefficient 0.6 Recalculated by fitting from [40]
IPMCA,min Minimal Ca
2+ pumping current 0.90 pA [50]
KCa,PMCA Half-saturation constant in Ca
2
+-dependent factor
0.18 μM Recalculated by fitting from [40]
kβ PMCA voltage sensitivity constant 100 mV [50]
kα PMCA voltage sensitivity constant 250 mV [50]
f PMCA,cGMP Additional fold-increase in electric
current due to cGMP
3 Recalculated by fitting from [40]
KcGMP,PMCA Half-saturation constant in the
cGMP-dependent regulatory Hill
function
0.50 μM Recalculated by fitting from [40]
nPMCA,cGMP Hill coefficient 1.7 Recalculated by fitting from [40]
Table 7.
Parameter values for the cGMP-dependent Ca2+ current via PMCA.
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the Ca2+ efflux via IP3R1 as proposed by [50]. That model is upgraded here
according to the experimental data of [36], with an additional regulatory factor
RIR1,cGMP, which accounts for the drop in Ca
2+ release after IP3 stimulation with
increasing cGMP levels [36]. General description of the Ca2+ flux across the SR
membrane through the IP3R1 channels (JIR1) follows [50]:









where gIR1is an overall maximal rate of the channel permeability and PIR1is the
channel open probability, which is a biphasic bell-shaped function of [Ca2+]i, and is
also dependent on the cytosolic IP3 and sarcoplasmic Ca
2+ concentrations ([IP3] and
[Ca2+]SR, respectively). It is modeled as in [50, 80]:















The regulatory factor RIR1,cGMP is a decaying Hill function that depends on the
cGMP concentration and is an upgrade from the previous model [50]. The proposed
function is the best fit to the measured decay of IP3-induced Ca
2+ release as a
function of cGMP concentration in isolated gastric SMC [36]:
RIR1,cGMP ¼ 1 f IR1,cGMP
cGMP½ nIR1,cGMP




where f IR1,cGMP is an additional fold decrease in the channel open probability due
to cGMP. f IR1,A, and f IR1,I in Eq. (29) are the fractions of the channel population
occupied by [Ca2+]i at the activation sites and inactivation sites, respectively. In this
way, the bell-shaped dependency on [Ca2+]i is achieved. Since activation is a fast










whereas the Ca2+-dependent IP3R1 inhibition is considered as slow and is




f IR1,I  f IR1,I
τIR1,I
, (31)











Description of all parameters and their values are presented in Table 8.
4.8.2 Variant B
Other results of Murthy and Zhou [20] provide another possible model descrip-
tion of cGMP-dependent IP3R1 inhibition. The experiment offers direct PKG or
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cGMP dependency of IP3-dependent Ca
2+ flux. The cGMP/PKG mediated phos-
phorylation of IP3R1 in microsomes was confirmed in the accompanying experi-
ment by immunoprecipitation. Hence, Murthy and Zhou [20] measured Ca2+
release through the phosphorylated IP3R1 within smooth muscle microsomes at
different IP3 concentrations. Prior to measurements, microsomes were either
treated with 0.5 μM PKG-Iα holoenzyme and 10 μM cGMP or left intact (control).
Ca2+ release was determined from the decrease in the steady-state microsomal
radioactive Ca2+ isotope content. In this way, two dose–response curves were
obtained [20]. Their best fits with a Hill function reveal almost the same Hill
coefficients (0.49 and 0.42, for the control and cGMP/PKG treated case, respec-
tively) and the same Vmax (100%) but significantly different half-saturation con-
stants Km, 1.17  103 μM and 2.35 μM, for the control and the cGMP/PKG treated
case, respectively. These two measured values represent two points to which any
function could virtually be fitted. Since this is highly unrealistic, we propose the use
of competitive, reversible enzyme inhibition kinetics, where cGMP represents an













Parameter Description Value References
gIR1 Maximal permeability rate of the channel 30 s
1 [50]
KIP3 Half saturation constant in the IP3-dependent
regulatory Hill function
0.65 μM [50]
KCa,SR Half saturation constant in the sarcoplasmic Ca
2+-
dependent regulatory Hill function
2  103 μM [50]
nIP3 Hill coefficient 4 [50]
nSR Hill coefficient 2 [50]
f IR1,cGMP Additional fold decrease in the channel open
probability due to cGMP
0.645 Recalculated by
fitting from [36]
KcGMP,IR1 Half saturation constant in the cGMP-dependent
regulatory Hill function
24.6 μM Recalculated by
fitting from [36]
nIR1,cGMP Hill coefficient 0.47 Recalculated by
fitting from [36]
KCa,A Half saturation constant in the cytosolic Ca
2+-
dependent regulatory Hill function
0.13 μM [50]
nA Hill coefficient 4 [50]
τIR1,I Characteristic transition time 6.0 s [50]
KCa,I Half saturation constant in the cytosolic Ca
2+-
dependent regulatory Hill function
0.35 μM [50]
nI Hill coefficient 4 [50]
Table 8.
Parameter values for the cGMP and IP3 -dependent open probability of IP3R1 – Variant a.
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where KIP3,cGMP,i = 2.35 μM, which is a measured half-saturation constant treated
with cGMP½ 0 = 10 μM, and KIP3,c = 1.17  10
3 μM, which is the corresponding
value at control experiment without added cGMP. Eq. (37) gives Ki,cGMP =
5.0  103 μM. The same calculation in which PKG is replacing cGMP in Eqs. (32)–
(34) with the value PKG½ 0 =0.50 μM yields Ki,PKG = 0.25  10
3 μM. The summary
of parameter values accounting for OPIP3,cGMP=PKG as a function of either cGMP or
PKG is presented in Table 9.
We offer here two different variants of the mathematical descriptions for the
cGMP impact on the IP3R1. Variant A seems more realistic as it contains the
description with saturating Hill function. On the other hand, variant B takes into
account the linear relationship on cGMP concentration, which might be question-
able at high cGMP concentrations. However, variant B offers an insight into the
strength of the inhibition on IP3R1 exerted by cGMP. Ki,cGMP and Ki,PKG values
indicate very strong inhibition. It is also worth mentioning that such an effect might
also arise from the experimental conditions since they were performed on the
isolated microsomes [20]. Before actual inclusion of either of both mechanisms into
a whole-cell-like model of VSMC, their careful model evaluation at different
dynamical levels of [Ca2+]i signaling, such as membrane potential, basal [Ca
2+]i,
different shapes and frequencies of [Ca2+]i signal, would be required.
4.9 The model of cGMP-mediated Ca2+-desensitization of the contractile
apparatus
Modeling of cGMP/PKG- dependent Ca2+-desensitization was first introduced
by Yang et al. [67], who considered that MLCP is directly activated by cGMP. They
modified the 4-state latch bridge model introduced by Hai and Murphy [13] by
considering a simple theoretical description of Ca2+/CaM-dependent MLCK activa-
tion and MLCP dependent dephosphorylation [67]. They also reduced the model
from 4 to 2 states of myosin species, phosphorylated and dephosphorylated (Mp and
M, respectively), being in equilibrium. Hence, the relative level of phosphorylated





Parameter Description Value References
KIP3,0 Half-saturation constant in the IP3-dependent regulatory
Hill function
0.65 μM [50]
nIP3 Hill coefficient 4 [50]
Ki,cGMP Apparent inhibition constant for cGMP-dependent
inhibition of IP3-dependent open probability of IP3R1
5.0  103 μM Recalculated
from [20]
Ki,PKG Apparent inhibition constant for PKG-dependent
inhibition of IP3-dependent open probability of IP3R1
0.25  103 μM Recalculated
from [20]
Table 9.
Parameter values for the cGMP and IP3 -dependent open probability of IP3R1 – Variant B.
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where kcat,MLCK is [Ca
2+]i dependent rate of phosphorylation (see [67]) and,
kcat,MLCP,b is a basal dephosphorylation rate that is multiplied by the cGMP-
dependent regulatory factor:
RMLCP,cGMP ¼ 1þ fMLCP,cGMP
cGMP½ nMLCP
cGMP½ nMLCP þ KnMLCPcGMP,MLCP
, (37)
where f cat,MLCP is an additional fold-increase in the MLCP-mediated Mp dephos-
phorylation rate due to cGMP. KcGMP,MLCP is a half-saturation constant within
cGMP-dependent regulatory Hill function with a Hill coefficient nMLCP.
The model of Yang et al. [67] demonstrated cGMP-mediated Ca2+-desensitiza-
tion by shifting the equilibrium MLC phosphorylation and force curves vs. [Ca2+]i
to the right. However, the model was not used to simulate the time-dependent
phosphorylation and force development. In this context, the model would not
accurately predict the results since Ca2+-dependent MLCK activation could not be
considered as a fast process [81, 82]. Also, the simplification from 4 to 2 states is
neither reasonable nor relevant if the model would account for the time-dependent
variables. Hence, we propose another modeling approach to tackle the cGMP-
dependent activation of MLCP. The proposed model considers the Michaelis–
Menten-type of enzyme kinetics for the rate of MLC dephosphorylation within the
4-state latch bridge kinetic scheme [83], yielding the velocity of MLCP dependent
dephosphorylation (VMLCP) of both phosphorylated myosin species, attached and






















where MLCP½ tot is the total MLCP concentration, KMLCP is a Michaelis–Menten
constant, and kcat,MLCP is a catalytic rate constant, for which we consider to be
cGMP-dependent as proposed by [67] in Eq. (35). All current parameters are
presented in Table 10.
A similar modeling approach for ROCK-dependent sensitization of the contrac-
tile apparatus was used in our previous work [64]. The whole model for all Ca2+/
CaM/MLCK interactions, all myosin species, and the time-dependent force devel-
opment is presented in different variants elsewhere [64, 81, 82, 84] and it comprises
more than 12 differential equations. That is a minor drawback of the model, but the
model proved itself in describing time-dependent force generation in rat airway
smooth muscle cells [64, 82]. Such an extended model would also allow the
Parameter Description Value References
kMLCP,b Basal dephosphorylation rate 8 s
1 [64]
fMLCP,cGMP Additional fold increase in dephosphorylation rate due to cGMP 1 [64]
nMLCP Hill ceofficient 2 [67]
KcGMP,MLCP Half saturation constant in a cGMP-dependent regulatory Hill
function
5.5 μM [67]
KMLCP Michaelis–Menten constant 10 μM [81]
MLCP½ tot Total MLCP concentration 2 μM [81]
Table 10.
Parameter values for cGMP-dependent Ca2+-desensitization of the contractile apparatus.
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modeling of other cGMP/PKG-mediated mechanisms of MLCP and MLCK regula-
tion by considering several different microscopic states of these two enzymes, such
as different phosphorylated states, interaction with telokin, CPI-17, etc. That would
allow the interconnection of different signal pathways and, hence, the simulation of
the effects of various agonists and inhibitors.
5. Conclusion
This work discusses previous and provides the novel cGMP/PKG-dependent
mechanisms at the molecular level accounting for their potential use in compre-
hensive whole-cell-like models of vascular smooth muscle contraction. Much has
been done in the fields of measurements and modeling of the cGMP/PKG effects on
the individual [Ca2+]i encoding and decoding mechanisms implicated in VSMC
contractility. However, especially in the modeling part, there is still room for
improvement and upgrading the existing models and building even multi-cellular
[85, 86] and systems-pharmacology based models [87]. We should also take into
consideration the importance of coupling the models of vascular smooth muscle
cells to endothelial cells that, in response to the shear stress of blood flow, produce
NO and other contractile and relaxation mediators [88, 89]. Moreover, the models
would enable simulations at the tissue and organ level [90]. However, many of such
multi-scale models are weak in describing mechanisms at the molecular level. That
is not an easy task since the number of variables and parameters and the model
complexity can increase tremendously. The other possibility to tackle that web of
interrelated interactions is by complex network approach [91]. However, a dynamic
modeling approach, as presented here, which is currently presented only at the level
of individual fluxes that need to be assembled into a comprehensive model, offers
many more options for studying the temporal dynamical behavior of the system
functioning, either under physiological or pathological conditions or after pharma-
cological intervention. The remarkable advantage and added value of such mathe-
matical models is that they describe the processes as dynamic ones. They often do
not consider only one single process but take into account mutual interactions
between several highly interrelated variables. In this way, they reach beyond the
intuitive thinking of direct and inverse proportions between certain variables,
which is often the case when interpreting the experimental results. However,
models hide other pitfalls, such as excessive simplicity or complexity, unfounded
predictions, prejudging, unawareness of the model’s limitations, and transfer of
models between different cell types and organisms, and much more. Nevertheless,
they represent a useful tool for in-depth insight into the system’s dynamical func-
tioning, distinguishing essential from nonessential mechanisms, and last but not
least, for highlighting the targets of pharmacological intervention.
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